Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Decide On Expanded Use Of Gardasil In Older Women In Mid-June

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Merck anticipates receiving an FDA decision by mid-June on expanding use of its human papillomavirus Gardasil to women aged 27 through 45

You may also be interested in...

Gardasil For Males Gets FDA OK; Next Up, Cost-Effectiveness Questions

CDC's Advisory Committee on Immunization Practices is slated to consider at an Oct. 21 meeting whether to recommend the vaccine to prevent genital warts in males.

Gardasil Label Expansion To Women 27-45 Delayed Until 2010, At The Earliest

Merck receives a second “complete response” letter from FDA related to its sBLA to extend indications for the vaccine to older women.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts